Great chatting with you @StephenPHansen. We’ve had our heads down for a while so it was nice to come out of the woodwork. 😉 biocentury.com/article/64587…
Having come out of yeast genetics labs during my PhD/postdoc days, it’s been hard not to be impressed by the promise of Lifemine’s platform. Congrats to @glostaman and team on the transformational partnership and financing: endpts.com/greg-verdine-will…
1
Very excited to be part of the story including at the company’s nucleation. For us, the Ambagon story began in 2019 with Michelle Arkin’s talk at Science2Startup here in Cambridge! Bring it back @LifeSciVC! 😉
Congratz to the exceptional Ambagon team + founders! $85M led by @NextechInvest brings total VC to >$100M after $18M seed by AbbVie, Merck, INKEF, DROIA and RA Capital. Also excited to welcome aboard Surveyor.
4
I’m coming out of hiding to say that we’re thrilled to be backing Nan Ji and PAQ Therapeutics for its Series A announced today. The TPD space continues to evolve and we’re very excited to continue to invest in this exciting modality. fiercebiotech.com/biotech/pa…
3
Peter Dudek retweeted
Relying on a bubbly immune cell that eats pathogens and often gathers around solid tumors, the team at Carisma Therapeutics hopes CAR-M can bring the benefits of cell therapy into places where CAR-T has consistently failed.
endpts.com/car-m-era-begins-…
Peter Dudek retweeted
Here is a head-to-head comparison of the he Pfizer/BioNTech and Moderna vaccines buff.ly/3ocII2r
Congrats to Hugh and the Imago team as it powers up to bring bomedemstat to more patients with myeloproliferative neoplasms.
Blood cancer player Imago Biosciences caps off an $80M Series C with an IPO promise for 2021 endpts.com/blood-cancer-play…
Peter Dudek retweeted
We've passed a key marker for the year --
Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019
By @MaxGelman
endpts.com/kymera-raising-17…
Peter Dudek retweeted
The approval of risdiplam, an RNA-targeted small-molecule splicing modulator, for patients with SMA is a landmark - a powerful example of how straight the line can sometimes be from scientific insight to patient benefit.
On the heels of its first IND, Carisma’s science makes the cover of the latest issue of @NatureBiotech nature.com/nbt/volumes/38/is…
2
Huge congrats to the team at Carisma for its first IND! Engineered macrophages are headed to the clinic. carismatx.com/carisma-therap…
2
Peter Dudek retweeted
Excited to partner with @sanofi to power up our IRAK4 program in immune-inflammatory diseases. Fulfilling our mission to ensure broadest patient impact of our degrader drugs while retaining value and growing our clinical and commercial capabilities. https://xitter.gq/t.co/RASXHBEWLS
Peter Dudek retweeted
The trillion dollar question. Why are COVID cases increasing while deaths are decreasing? The answer is simple. It's called Simpson's paradox and it's the result of incorrectly pooling data and arriving at a false conclusion. A thread 1/9 #COVID19 #ThursdayThoughts
This blew my mind. Eight papers, same figures and tables, different authors and journals. Wow. #scienceintegrity scienceintegritydigest.com/2…
This figure from a recent Cell Metabolism review sparked an internal debate about science and communication. What's your favorite facepalm-inducing scientific diagram? Rules: must have been made (or reviewed) by a real scientist #sciencetwitter
I’m super excited to be joining the @hotspotthera story today as it closes its latest financing with $65M! hotspotthera.com/press_relea…
Peter Dudek retweeted
New study by @IdoAmitLab on scRNA-seq in mild (n=3) vs severe (n=6) COVID-19 patient, w/ computational disentangling of cells directly infected by SARS-CoV-2 vs those indirectly impacted.
sciencedirect.com/science/ar…
Peter Dudek retweeted
Encouraging news for #COVID19 vaccines: preprint shows inactivated #SARSCoV2 virus injected into rodents & monkeys induces neutralizing antibodies against 10 representative SARS-CoV-2 strains & provides protection from live virus in monkeys, w/o AME/ADE. biorxiv.org/content/10.1101/…















